Trexquant Investment LP Has $479,000 Position in Medifast Inc $MED

Key Points

• Trexquant Investment LP reduced its stake in Medifast Inc by 39.0% in the first quarter, holding 35,537 shares worth approximately $479,000 after selling 22,767 shares.
• Medifast recently reported $0.04 earnings per share, surpassing the consensus estimate of ($0.22), with revenues of $105.56 million exceeding expectations of $96.10 million.
• Institutional investors and hedge funds collectively own 95.51% of Medifast's stock, indicating strong institutional interest in the company.

Trexquant Investment LP lessened its stake in shares of Medifast Inc (NYSE:MED - Free Report) by 39.0% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 35,537 shares of the specialty retailer's stock after selling 22,767 shares during the quarter. Trexquant Investment LP owned about 0.32% of Medifast worth $479,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Peapod Lane Capital LLC acquired a new stake in shares of Medifast during the 1st quarter worth about $933,000. GAMMA Investing LLC lifted its stake in shares of Medifast by 3,207.2% during the 1st quarter. GAMMA Investing LLC now owns 3,208 shares of the specialty retailer's stock worth $43,000 after buying an additional 3,111 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of Medifast by 11.4% during the 4th quarter. Two Sigma Investments LP now owns 232,069 shares of the specialty retailer's stock worth $4,089,000 after buying an additional 23,822 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of Medifast by 23.5% during the 4th quarter. Wells Fargo & Company MN now owns 6,459 shares of the specialty retailer's stock worth $114,000 after buying an additional 1,227 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Medifast by 0.9% during the 4th quarter. Northern Trust Corp now owns 101,775 shares of the specialty retailer's stock worth $1,793,000 after buying an additional 871 shares during the last quarter. Institutional investors and hedge funds own 95.51% of the company's stock.

Medifast Stock Up 1.9%

Shares of Medifast stock opened at $13.81 on Tuesday. Medifast Inc has a twelve month low of $11.57 and a twelve month high of $21.98. The company has a 50-day simple moving average of $13.97 and a two-hundred day simple moving average of $13.62. The stock has a market capitalization of $151.75 million, a price-to-earnings ratio of 43.15 and a beta of 0.82.

Medifast (NYSE:MED - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The specialty retailer reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.26. Medifast had a net margin of 0.76% and a return on equity of 2.00%. The business had revenue of $105.56 million during the quarter, compared to analysts' expectations of $96.10 million. Medifast has set its Q3 2025 guidance at -0.600-0.00 EPS. On average, sell-side analysts anticipate that Medifast Inc will post 0.51 earnings per share for the current fiscal year.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.

Want to see what other hedge funds are holding MED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medifast Inc (NYSE:MED - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.